NasdaqGS - Nasdaq Real Time Price USD

Neurocrine Biosciences, Inc. (NBIX)

124.54
+0.02
+(0.02%)
As of 11:46:57 AM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NBIX

Recent News: NBIX

View More
CPRX or NBIX: Which Is the Better Value Stock Right Now?

CPRX or NBIX: Which Is the Better Value Stock Right Now?
Zacks 2 days ago

Neurocrine Biosciences' Ingrezza to Meet Fiscal 2025 Sales Outlook, RBC Capital Says
PREMIUM
MT Newswires 2 days ago
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia

Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
PR Newswire 3 days ago
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
GlobeNewswire 5 days ago
Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched

Neurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched
Insider Monkey 7 days ago
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
PR Newswire 7 days ago
Exploring 3 High Growth Tech Stocks In The US Market

Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St. 13 days ago
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
PR Newswire 20 days ago
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
PR Newswire 20 days ago
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
PR Newswire 20 days ago
GRFS or NBIX: Which Is the Better Value Stock Right Now?

GRFS or NBIX: Which Is the Better Value Stock Right Now?
Zacks 21 days ago
View More

Related Tickers

UTHR United Therapeutics Corporation
321.07
-0.90%
 
RDY Dr. Reddy's Laboratories Limited
15.60
+5.76%
 
HCM HUTCHMED (China) Limited
15.22
-0.52%
 
TAK Takeda Pharmaceutical Company Limited
14.95
-0.53%
 
ELAN Elanco Animal Health Incorporated
13.45
-0.07%
 
ALKS Alkermes plc
31.21
-1.05%
 
DVAX Dynavax Technologies Corporation
9.94
+0.46%
 
AMRX Amneal Pharmaceuticals, Inc.
7.20
-0.21%
 
BCRX BioCryst Pharmaceuticals, Inc.
11.01
-0.27%
 
HLN Haleon plc
11.08
+1.28%